Prognostic value of Bmi-1 oncoprotein expression in NSCLC patients: a tissue microarray study
- 9 February 2008
- journal article
- Published by Springer Nature in Zeitschrift für Krebsforschung und Klinische Onkologie
- Vol. 134 (9), 1037-1042
- https://doi.org/10.1007/s00432-008-0361-y
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinomaZeitschrift für Krebsforschung und Klinische Onkologie, 2007
- Circulating Bmi-1 mRNA as a possible prognostic factor for advanced breast cancer patientsBreast Cancer Research, 2007
- Bmi-1 Is a Novel Molecular Marker of Nasopharyngeal Carcinoma Progression and Immortalizes Primary Human Nasopharyngeal Epithelial CellsCancer Research, 2006
- BMI1 is a target gene of E2F-1 and is strongly expressed in primary neuroblastomasNucleic Acids Research, 2006
- Expression of the p16INK4a gene product, methylation of the p16INK4a promoter region and expression of the polycomb-group gene BMI-1 in squamous cell lung carcinoma and premalignant endobronchial lesionsLung Cancer, 2005
- Three Emerging New Drugs for NSCLC: Pemetrexed, Bortezomib, and CetuximabThe Oncologist, 2005
- Unique Polycomb Gene Expression Pattern in Hodgkin's Lymphoma and Hodgkin's Lymphoma-Derived Cell LinesThe American Journal of Pathology, 2004
- Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomasNature, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Stabilization of Chromatin Structure by PRC1, a Polycomb ComplexCell, 1999